Crossmark

Case report: primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790 M mutation

Crossref DOI link: https://doi.org/10.1186/s12885-018-4991-4

Published Online: 2018-11-06

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zheng, Lin-Peng

Chen, Li-Ying

Liao, Xing-Yun

Xu, Zi-Han

Chen, Zheng-Tang

Sun, Jian-Guo
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (No. 81672841)

Clinical Innovation Foundation of Army Medical University (yclkt-201408)

Wu Jieping Medical Foundation (320.6799.15037)
License Information

Text and Data Mining valid from 2018-11-06
More Information

Article History

Received: 28 February 2018

Accepted: 24 October 2018

First Online: 6 November 2018

Ethics approval and consent to participate

: The study was approved by the ethics committee of the Xinqiao Hospital of Army Medical University. The tissue samples used in this study have been collected in Xinqiao Hospital of Army Medical University. We obtained written informed consent from the patient prior to the study.

: Written informed consent was obtained from the patient’s daughter for publication of this case report.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.